|
Downgrade
| ShowHide Related Items >><< - 04/15/21
- Thermo Fisher to acquire PPD, Inc. for $47.50 per share
- 04/15/21
- Thermo Fisher to acquire PPD, Inc. for $47.50 per share
- 04/14/21
- PPD trading resumes
- 04/14/21
- PPD trading halted, volatility trading pause
- $494.70 /
+16.97 (+3.55%) - 04/15/21
- Thermo Fisher to acquire PPD, Inc. for $47.50 per share
- 04/15/21
- Thermo Fisher to acquire PPD, Inc. for $47.50 per share
- 04/12/21
- Thermo Fisher: FDA grants EUA for high-throughput COVID-19 Test
- 03/24/21
- Thermo Fisher to offer integrated COVID-19 testing to U.S. school districts
- 08:52 Today William Blair
- PPD downgraded to Market Perform from Outperform at William Blair
- 08:26 Today Evercore ISI
- Thermo Fisher price target raised to $540 from $525 at Evercore ISI
- 08:22 Today Evercore ISI
- PPD downgraded to In Line from Outperform at Evercore ISI
- 06:54 Today Deutsche Bank
- PPD downgraded to Hold from Buy at Deutsche BankThermo Fisher
- $494.70 /
+16.97 (+3.55%) - 08:52 Today William Blair
- PPD downgraded to Market Perform from Outperform at William Blair
- 08:26 Today Evercore ISI
- Thermo Fisher price target raised to $540 from $525 at Evercore ISI
- 06:54 Today Deutsche Bank
- PPD downgraded to Hold from Buy at Deutsche BankThermo Fisher
- 05:19 Today KeyBanc
- PPD downgraded to Sector Weight on takeover at KeyBanc
- 02/23/21
- PPD sees 2021 adjusted EPS $1.37-$1.45, consensus $1.39
- 02/23/21
- PPD sees Q1 adjusted EPS 30c-32c, consensus 32c
- 02/23/21
- PPD reports Q4 adjusted EPS 39c, consensus 36c
- 10/27/20
- PPD sees Q4 revenue $1.26B-$1.3B, consensus $1.15B
- $494.70 /
+16.97 (+3.55%) - 02/01/21
- Thermo Fisher sees FY21 EPS $21.62, consensus $20.74
- 02/01/21
- Thermo Fisher reports Q4 adjusted EPS $7.09, consensus $6.56
- 12/01/20
- Thermo Fisher raises FY20 adjusted EPS view to $19.17, consensus $18.34
- 10/21/20
- Thermo Fisher sees FY20 EPS $18.27, consensus $15.92
|
|
Recommendations
|
William Blair analyst Tim… ShowHide Related Items >><< AVIR Atea Pharmaceuticals - $46.01 /
-8.315 (-15.31%) - 03/07/21
- Atea Pharmaceuticals presents Phase 1 results for AT-527
- 02/19/21
- Atea Pharmaceuticals announces Chugai in-license of AT-527 from Roche
- 02/08/21
- Atea Pharmaceuticals announces data on 'potent activity' of AT-527 in SARS-CoV-2
- 02/04/21
- Atea doses first patient in Phase 2 trial of AT-527 in COVID-19 patients
- 04/15/21
- Nabriva announces start of exclusive distribution of Sivextro in U.S.
- 04/15/21
- Sutro Biopharma earns $15M milestone payment from Merck
- 04/15/21
- Merck to discontinue development of MRK-7110 in COVID-19 treatment
- 04/15/21
- Merck to proceed with Ph3 study of molnupiravir in outpatients, not inpatients
AVIR Atea Pharmaceuticals - $46.01 /
-8.315 (-15.31%) - 01/29/21 JPMorgan
- Atea Pharmaceuticals price target raised to $66 from $45 at JPMorgan
- 11/24/20 Evercore ISI
- Atea Pharmaceuticals initiated with an Outperform at Evercore ISI
- 11/24/20 Morgan Stanley
- Atea Pharmaceuticals initiated with an Overweight at Morgan Stanley
- 11/24/20 JPMorgan
- Atea Pharmaceuticals initiated with an Overweight at JPMorgan
- 04/12/21 B. Riley
- B. Riley calls Agenus the next Seagen, reiterates $8 target
- 04/08/21 Alliance Global Partners
- Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
- 04/08/21 H.C. Wainwright
- Alkermes collaboration not as big as investors wanted, says H.C. Wainwright
- 04/07/21 Mizuho
- Mizuho sees Alkermes, Merck collaboration as important next step for nemvaleukin
- 02/04/21
- Merck sees FY21 adjusted EPS $6.48-$6.68, consensus $6.41
- 02/04/21
- Merck reports Q4 adjusted EPS $1.32, consensus $1.38
- 02/03/21
- Notable companies reporting before tomorrow's open
- 02/03/21
- Notable companies reporting before tomorrow's open
|
|
On The Fly
|
Check out this morning's… ShowHide Related Items >><< - 03/09/21
- State Street sees Q1 fee revenue growth better than previous guidance
- 02/18/21
- State Street appoints Theresa McLaughlin as global CMO
- 01/20/21
- State Street to eliminate 1,200 positions this year
- 01/19/21
- State Street sees Q1 NII down about 68% sequentially
- 07:12 Today
- AstraZeneca reports U.S. clearance of proposed acquisition of Alexion
- 03/26/21
- Arcutis Biotherapeutics announces updates to its executive team
- 03/16/21
- AstraZeneca withdraws FTC notification on Alexion deal, plans to refile
- 02/22/21
- Arcturus Therapeutics acquires exclusive license from Alexion
- 04/08/21
- Royalty Pharma acquires OXLUMO royalty interest from Dicerna for up to $240M
- 04/08/21
- Royalty Pharma acquires Oxlumo royalty interest from Dicerna for $180M upfront
- 03/30/21
- Dicerna announces data from preclinical studies of GalXC-Plus RNAi technology
- 03/04/21
- Dicerna, Roche begin combo trial of GalXC for chronic HBV treatment
- 06:27 Today
- Citizens Financial CEO says 'confident' in outlook for balance of year
- 06:24 Today
- Citizens Financial reports Q1 net interest margin 2.76% vs. 3.10% a year ago
- 01/27/21
- Citizens announces consumer financing partnership with BJ's Wholesale Club
- 01/20/21
- Citizens Financial sees high single digit decrease in FY21 NIM
- 07:40 Today
- Ally Financial reports Q1 return on equity 21.7%, core ROTCE 24.1%
- 07:39 Today
- Ally Financial reports Q1 net interest margin 3.16%, up 50 bps y/y
- 03/11/21
- CarLotz announces strategic relationship with Ally Financial
- 02/16/21
- Soros buys Ally Financial, exits DraftKings in Q4
- 08:30 Today
- PPG says expects to complete the acquisitions of Tikkurila, Worwag during Q2
- 04/15/21
- PPG sees broad-based global coatings demand
- 04/01/21
- PPG opens China Application Innovation Center in Zhangjiagang
- 03/31/21
- PPG announces paint agreement with Vizient
- 08:53 Today
- Morgan Stanley says investment banking pipelines 'healthy across products'
- 08:43 Today
- Morgan Stanley says Archegos exit 'money well spent'
- 08:39 Today
- Morgan Stanley says Q1 marked by 'numerous performance records'
- 04/15/21
- Congress to host big bank CEOs for hearings the week of May 24
- 04/14/21
- BNY Mellon chosen as transfer agent of Charles Schwab Investment Management
- 03/22/21
- AFL-CIO teams with Wilmington Trust, BNY Mellon on retirement plan options
- 02/16/21
- Amundi US appoints BNY Mellon as fund service provider
- 02/11/21
- BNY Mellon announces formation of new digital assets unit
- 02/08/21
- Editas Medicine appoints James Mullen as CEO
- 01/11/21
- Editas Medicine Chief Scientific Officer Charles Albright, Ph.D to step down
- 01/11/21
- Editas Medicine says FDA clears initiation of EDIT-301 clinical trial
- 12/21/20
- Editas leads gene editing stocks higher with 46% rally to $95.42
- 07:12 Today
- AstraZeneca reports U.S. clearance of proposed acquisition of Alexion
- 04/14/21
- Denmark to continue vaccine rollout without AstraZeneca COVID-19 vaccine
- 04/14/21
- AstraZeneca's Tagrisso approved in China in early lung cancer
- 04/12/21
- AstraZeneca's DARE-19 ph.3 trial of Farxiga in COVID-19 failed primary endpoint
- 04/09/21 Deutsche Bank
- State Street price target raised to $100 from $97 at Deutsche Bank
- 04/07/21 Barclays
- State Street price target raised to $104 from $99 at Barclays
- 04/01/21 Wells Fargo
- State Street price target raised to $90 from $83 at Wells Fargo
- 04/01/21 Morgan Stanley
- State Street price target raised to $103 from $102 at Morgan Stanley
- 03/23/21
- Fly Intel: Top five analyst downgrades
- 03/23/21 SVB Leerink
- SVB Leerink moving to sidelines on Alexion, five others on industry concerns
- 03/23/21 SVB Leerink
- Alexion downgraded to Market Perform from Outperform at SVB Leerink
- 02/04/21 Piper Sandler
- Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler
- 04:53 Today Goldman Sachs
- Dicerna initiated with a Buy at Goldman Sachs
- 03/18/21
- Dicerna to hold a webinar on DCR-AUD disorder
- 03/18/21
- Dicerna to hold a webinar on DCR-AUD disorder
- 03/02/21 H.C. Wainwright
- Dicerna price target raised to $40 from $35 at H.C. Wainwright
EBET Esports Technologies - $36.05 /
+12.95 (+56.06%) - 04/09/21 Jefferies
- Citizens Financial price target raised to $47 from $42 at Jefferies
- 04/07/21 Barclays
- Citizens Financial price target raised to $54 from $49 at Barclays
- 04/01/21 Deutsche Bank
- Citizens Financial price target raised to $50 from $44 at Deutsche Bank
- 03/30/21 Stephens
- Citizens Financial price target raised to $54 from $45 at Stephens
- 04/15/21 JPMorgan
- Ally Financial price target raised to $54 from $48 at JPMorgan
- 04/13/21 Wells Fargo
- Ally Financial price target raised to $57 from $51 at Wells Fargo
- 04/12/21 BofA
- Ally Financial reinstated with a Buy at BofA
- 04/08/21 Evercore ISI
- Ally Financial initiated with an Outperform at Evercore ISI
- 04/15/21 Citi
- Citi opens '30-day negative catalyst watch' on Axalta, PPG
- 04/07/21 Wells Fargo
- PPG price target raised to $173 from $165 at Wells Fargo
- 03/15/21 Credit Suisse
- PPG assumed with a Neutral at Credit Suisse
- 01/26/21 BofA
- PPG upgraded to Buy from Neutral at BofA
- 04/09/21 JMP Securities
- Goldman Sachs price target raised to $400 from $338 at JMP Securities
- 04/07/21 Barclays
- Morgan Stanley price target raised to $98 from $95 at Barclays
- 04/01/21 Deutsche Bank
- Morgan Stanley price target raised to $79 from $68 at Deutsche Bank
- 04/01/21 UBS
- Morgan Stanley price target raised to $92 from $84 at UBS
- 04/09/21 Deutsche Bank
- BNY Mellon price target raised to $54 from $50 at Deutsche Bank
- 04/07/21 Barclays
- BNY Mellon price target raised to $57 from $55 at Barclays
- 03/26/21 JPMorgan
- JPMorgan sees BNY Mellon, Wells Fargo among banks with most buyback capacity
- 03/24/21
- Fly Intel: Top five analyst upgrades
- 04:56 Today Goldman Sachs
- Editas Medicine initiated with a Sell at Goldman Sachs
- 03/22/21 Credit Suisse
- Editas Medicine initiated with an Outperform at Credit Suisse
- 03/17/21 Guggenheim
- Editas Medicine assumed with a Neutral at Guggenheim
- 03/01/21 Barclays
- Editas Medicine downgraded to Equal Weight from Overweight at Barclays
- 04/14/21 Guggenheim
- Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
- 04/12/21
- Fly Intel: Top five analyst downgrades
- 04/12/21 B. Riley
- B. Riley calls Agenus the next Seagen, reiterates $8 target
- 04/12/21 Argus
- AstraZeneca downgraded to Hold from Buy at Argus
- 07:44 Today
- State Street reports Q1 ex-items EPS $1.47, consensus $1.35
- 04/15/21
- Notable companies reporting before tomorrow's open
- 04/15/21
- Notable companies reporting before tomorrow's open
- 01/19/21
- State Street reports Q4 EPS $1.39, consensus $1.56
- 02/04/21
- Alexion reports Q4 EPS $2.96, consensus $2.56
- 02/04/21
- Alexion reports Q4 EPS $2.96, consensus $2.56
- 10/29/20
- Alexion raises 2020 non-GAAP EPS view to $11.70-$12.00 from $10.65-$10.95
- 10/29/20
- Alexion reports Q3 non-GAAP EPS $3.24, consensus $2.60
- 02/25/21
- Dicerna reports FY20 EPS ($1.52), consensus ($1.05)
- 11/05/20
- Dicerna reports Q3 EPS (29c), consensus (20c)
- 06:23 Today
- Citizens Financial reports Q1 underlying EPS $1.41, consensus 97c
- 06:21 Today
- Citizens Financial reports Q1 underlying EPS $1.41, consensus 97c
- 04/15/21
- Notable companies reporting before tomorrow's open
- 04/15/21
- Notable companies reporting before tomorrow's open
- 07:37 Today
- Ally Financial reports Q1 adjusted EPS $2.09, consensus $1.15
- 04/15/21
- Notable companies reporting before tomorrow's open
- 04/15/21
- Notable companies reporting before tomorrow's open
- 01/22/21
- Ally Financial reports Q4 adjusted EPS $1.60, consensus $1.05
- 08:30 Today
- PPG sees Q2 adjusted EPS $2.15-$2.20, consensus $2.10
- 04/15/21
- PPG reports Q1 EPS $1.88, consensus $1.56
- 04/15/21
- Notable companies reporting after market close
- 01/22/21
- PPG sees Q1 adjusted EPS $1.55-$1.61, consensus $1.89
- 07:34 Today
- Morgan Stanley reports Q1 EPS $2.19, consensus $1.70
- 04/15/21
- Notable companies reporting before tomorrow's open
- 04/15/21
- Notable companies reporting before tomorrow's open
- 04/14/21
- Fly Intel: What to watch in next round of big bank earnings reports
- 06:34 Today
- BNY Mellon reports Q1 EPS 97c, consensus 87c
- 04/15/21
- Notable companies reporting before tomorrow's open
- 04/15/21
- Notable companies reporting before tomorrow's open
- 01/20/21
- BNY Mellon reports Q4 ex-items EPS 96c, consensus 91c
- 02/25/21
- Editas Medicine reports Q4 EPS ($1.00), consensus (74c)
- 11/05/20
- Editas Medicine reports Q3 EPS 12c, consensus (64c)
- 04/07/21
- EMA says benefits of AstraZeneca Covid vaccine outweigh side effects
- 02/11/21
- AstraZeneca sees FY21 core EPS $4.75-$5.00
- 02/11/21
- AstraZeneca reports Q4 core EPS $1.07, total revenue $7.41B
- 11/05/20
- AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage
|
|
Hot Stocks
| ShowHide Related Items >><< - 03/17/21
- Arch Capital to acquire Westpac Lenders Mortgage Insurance Ltd
- 01/21/21
- Arch Capital estimates Q4 catastrophe losses of $155M-$165M
- 04/14/21 RBC Capital
- Arch Capital price target raised to $47 from $41 at RBC Capital
- 03/29/21 Deutsche Bank
- Arch Capital price target raised to $46 from $42 at Deutsche Bank
- 01/19/21 JMP Securities
- Arch Capital upgraded to Outperform from Market Perform at JMP Securities
- 01/04/21 JPMorgan
- Arch Capital price target raised to $36 from $30 at JPMorgan
- 02/09/21
- Arch Capital reports Q4 operating EPS 56c, consensus 38c
- 10/29/20
- Arch Capital reports Q4 ops EPS 29c, consensus 16c
|
|
Hot Stocks
| ShowHide Related Items >><< - 11/12/20
- Energizer falls -11.7%
- 11/12/20
- Energizer falls -10.9%
- 11/12/20
- Energizer falls -9.2%
- 11/12/20
- Energizer announces up tp 7.5M share stock repurchase plan
- 07:47 Today
- EU passenger car registrations up 87.3% in March, up 3.2% in Q1
- 04/08/21
- Verizon, Honda test how 5G can improve safety for connected, autonomous vehicles
- 04/01/21
- Honda reports March U.S. sales up 92.5% to 148,538 vehicles
- 04/01/21
- Honda reports Q1 U.S. sales up 16.2% to 347,091 vehicles
- 07:24 Today JPMorgan
- Energizer price target raised to $52 from $51 at JPMorgan
- 02/24/21
- Fly Intel: Top five analyst downgrades
- 02/24/21 Goldman Sachs
- Energizer downgraded to Neutral from Buy at Goldman Sachs
- 02/09/21
- Fly Intel: Top five analyst downgrades
- 02/18/21 Daiwa
- Honda downgraded to Outperform from Buy at Daiwa
- 08/06/20 DZ Bank
- Honda downgraded to Sell from Hold at DZ Bank
- 07/28/20 Macquarie
- Honda initiated with an Outperform at Macquarie
- 07/14/20 CLSA
- Honda upgraded to Buy from Underperform at CLSA
- 02/08/21
- Energizer raises FY21 adjusted EPS view to $3.10-$3.40 from $2.95-$3.25
- 02/08/21
- Energizer reports Q1 adjusted EPS $1.17, consensus 89c
- 11/12/20
- Energizer sees FY21 adj. EPS $2.95-$3.25, consensus $3.13
- 11/12/20
- Energizer reports Q4 adj. EPS 59c, consensus 81c
- 02/09/21
- Honda reports Q3 revenue Y3.77T vs. Y3.75T last year
- 11/06/20
- Honda reports 1H EPS Y92.70 vs. Y209.63 last year
- 11/06/20
- Honda reports Q2 revenue Y3.65T vs. Y3.73T last year
- 12/07/20
- Energizer, Duracell dismiss rival suits over battery life claims, Reuters says
- 03/22/21
- California senators urge Biden to set end date for gas car sales, Reuters report
- 03/17/21
- Toyota, Honda halting some NA production amid supply shortages, WSJ reports
- 01/11/21
- GM partnering with 'best startups' on EV battery technology, Reuters says
- 01/07/21
- Honda to reduce car output by roughly 4,000 units this month, Nikkei Asia says
- 02/08/21
- Fly Intel: Wall Street's top stories for Monday
- 02/08/21
- Fly Intel: Wall Street's top stories at midday
- 02/08/21
- Fly Intel: Pre-market Movers
- 01/26/21
- Fly Intel: What to watch in Microsoft earnings report
- 01/19/21
- Fly Intel: Wall Street's top stories for Tuesday
- 01/19/21
- Fly Intel: Wall Street's top stories at midday
|